Akums Drugs And Pharmaceuticals Limited · NSE:AKUMS
Akums Drugs And Pharmaceuticals — Q2 FY25 Earnings Presentation
26 slides from Akums Drugs And Pharmaceuticals's earnings presentation, Nov 9, 2024
Slide 1: Exchange filing cover letter for investor presentation
Ref: Akums/Exchange/2024-25/28 November 09, 2024 To, To, The Listing Department The Listing Department National Stock Exchange of India Ltd BSE Limited Exchange Plaza, C-1, Block G, Rotunda Building, Phiroze Bandra Kurla Complex, Jeejeebhoy Towers, Dalal Street, Bandra (E),Mumbai – 400 051 Fort, Mum
Slide 2: Investor Presentation November 2024
Investor Presentation November 2024
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Akums Drugs and Pharmaceuticals Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscr
Slide 4: Managing Directors' Message
Managing Directors’ Message We take pleasure in declaring the Q2 results of the company and thank all the stakeholders and shareholders for there continued support to the company. We continue to serve over 1,500 clients annually, a testament of our wide range of product basket, robust manufacturing
Slide 5: Q2 FY24-25 Financial Performance Highlights
Q2 FY24-25 Financial Performance Highlights
Slide 6: Key Highlights – September 2024
Key Highlights – September 2024 Adjusted EBITDA* declined to Rs. 1,347 mn (12.9%) from Rs. 1,871 mn (15.8%) ,gross margins Adjusted PAT** increased to Rs. 667 mn (6.4%) however, improved to 42.3% from 40.6% on YoY from Rs. 612 mn (5.2%) YoY basis basis Cash flow from operations for H/E Sept 2024 is
Slide 7: Consolidated Quarterly Performance Highlights (1/2)
Consolidated Quarterly Performance Highlights (1/2) Total Income (INR Mn) Adjusted Ebitda1 (INR Mn) Adjusted PAT2 (INR Mn) 2.0% Margin Margin 5.6% 6.4 % 10,257 10,466 12.7% 12.9% % % 3.0% 667 16.2% 1,307 1,347 573 Q1 FY 25 Q2 FY 25 Q1 FY 25 Q2 FY 25 Q1 FY 25 Q2 FY 25 Net Debt (INR Mn) Working Capita
Slide 8: Consolidated Quarterly Performance Highlights (2/2)
Consolidated Quarterly Performance Highlights (2/2) Total Income (INR Mn) Adjusted Ebitda1 (INR Mn) Margin 15.8% 12.9% 11,880 % -11.9% 1,871 -28.0% 10,466 1,347 Q2 FY 24 Q2 FY 25 Q2 FY 24 Q2 FY 25 Adjusted PAT2 (INR Mn) Margin 5.2% 6.4 % % 8.9% 667 612 Q2 FY 24 Q2 FY 25 (1) Adjusted EBITDA = Profit
Slide 9: Consolidated Half Yearly Performance Highlights
Consolidated Half Yearly Performance Highlights Total Income (INR Mn) Adjusted Ebitda1 (INR Mn) Margin 13.6% 12.8% % -4.3% 2,951 21,660 -10.1% 20,722 2,654 H1 FY 24 H1 FY 25 H1 FY 24 H1 FY 25 Adjusted PAT2 (INR Mn) Margin 4.6% 6.0% % 25.4% 1,240 989 H1 FY 24 H1 FY 25 (1) Adjusted EBITDA = Profit bef
Slide 10: Segmental Financials
Segmental Financials CDMO (INR Mn) Branded and Generic Formulations (INR Mn) API (INR Mn) Margin % 20.0% 15.4% Margin % 4.5% 10.3% Margin % -22.2% -24.0% -15.0% -5.9% 9,401 1,859 7.7% 1,750 7,987 552 594 -34.8% 1,882 1,227 83 180 Reven u e EBITDA Reven u e EBITDA Reven u e EBITDA Q2 FY24 Q2 FY25 Q2
Slide 11: Summary Profit and Loss Statement
Summary Profit and Loss Statement P/L (Rs Mn) Q2 FY 25 Q1 FY 25 Q2 FY 24 H1 FY 25 H1 FY 24 Revenue 10,331 10,191 11,813 20,522 21,511 Other Income 135 65 68 200 149 Total income 10,466 10,257 11,880 20,722 21,660 COGS 5,960 5,960 7,017 11,920 12,952 Employee Cost 1,801 1,762 1,639 3,563 3,204 Other
Slide 12: Summary Segmental Statement
Summary Segmental Statement Segmental (Rs Mn) Q2 FY 25 Q1 FY 25 Q2 FY 24 H1 FY 25 H1 FY 24 CDMO Revenue 7,987 7,820 9,401 15,807 16,806 EBITDA 1,227 1,212 1,882 2,439 2,950 EBIDTA Margin 15.4% 15.5% 20.0% 15.4% 17.6% API Revenue 594 697 552 1,291 933 EBITDA -143 -122 -123 -264 -210 EBIDTA Margin -24
Slide 13: Summary Balance Sheet Statement
Summary Balance Sheet Statement Liabilities(Rs Mn) Sept 2024 March 2024 Assets (Rs Mn) Sept 2024 March 2024 Total Equity 28,470 7,205 Non Current Assets 16,468 15,755 Equity Share Capital 306 286 Property, plant and equipment 11,355 10,649 Other Equity 28,029 6,809 Right-of-use assets 1,137 1,172 No
Slide 14: Summary Cash flow statement
Summary Cash flow statement Cash flow (Rs Mn) H1 FY 25 H1 FY 24 Net profit before Tax 1,791 -717 Add/Less: Non cash adjustments 811 3,662 Working Capital changes -1,568 -1,984 Cash generated from operations 1,033 961 Direct taxes Paid (net) -325 -328 Net cash flow generated from operating activities
Slide 15: Key Performance Indicators (KPIs)
Key Performance Indicators (KPIs) Quarter ended Half year ended Year ended S. No. Financial KPIs Unit 30-Sep-24 30-Jun-24 30-Sep-23 30-Sep-24 30-Sep-23 31-Mar-24 (a) Revenue from operations (₹ in m illion) 10,330.87 10,191.13 11,812.52 20,522.00 21,511.38 41,781.82 (b) EBITDA (1) (₹ in m illion) 1,3
Slide 16: Key Performance Indicators (cont'd)
Key Performance Indicators (cont’d) Notes: (1) EBITDA refers to sum of EBIT and depreciation and amortization expense. (2) EBITDA margin is calculated as EBITDA divided by total income. (3) EBIT refers to earnings before interest and tax, calculated as the sum of restated profit/(loss) before share
Slide 17: IPO proceeds utilization
IPO proceeds utilization The Company successfully got listed on 6 August 2024. Post listing, the Company received Rs. 6,373.70 million (net of offer expenses borne by Company) to be spent as mentioned. Purpose of Funds Amount Amount Utilised Remaining Amount (in million) (in million) (in million) Lo
Slide 18: India's Largest CDMO
Akums has a strategic presence across the pharmaceutical value chain driven by large R&D and manufacturing capabilities which reflects in the diverse and longstanding client relationships. 4,959 Cr 4,146 1,524 220+ (49.6bn) units Commercialized Customers; serving Innovative formulations across 26 ou
Slide 19: Two Decades' Legacy of Expertise, Experience and Trust
Two Decades’ Legacy of Expertise, Experience and Trust 2004–2010 2010–2021 2021 – 2024 Build Strengthen Accelerate Incorporated in April 2004 Dedicated facilities for Hormones, In Nov 2019, Quadria Capital(3) Set up of first plant for oral Cosmetics and Dermatology bought a minority stake (1
Slide 20: Akums has a right to win in a large pharma opportunity
Akums has a right to win in a large pharma opportunity 1 Largest India Focused CDMO with diverse client base 2 Comprehensive Offerings With Advanced Manufacturing Capabilities 3 Large and Growing R&D Capabilities Across Product Portfolio 4 Strategic Presence Across the Pharmaceutical Value Chain 5 E
Slide 21: Largest India Focused CDMO with diverse client base
1 Largest India Focused CDMO1 with diverse client base 10.0% share by value in 30.2% share in Indian 18,500+ 4,000+ 60+ total addressable Indian Domestic CDMO market SKUs manufactured in Formulations Dosage Forms domestic CDMO in FY242 in FY24 by value2 FY24 Signifcant nase of CDMO Clients… .. with
Slide 22: Technologically Advanced Manufacturing Capabilities
2 Technologically Advanced Manufacturing Capabilities Annual Capacity Location Year Dosage Forms Key Accreditations1 (Cr units) 1 Haridwar 2004 649 Oral Solids 2 Haridwar 2007 15 Oral Liquids 3 Haridwar 2007 39 Sterile Preparations 4 Hormonal – Oral, Injectables and Haridwar 2010 244 Topicals 5 Hari
Slide 23: Extensive R&D Capabilities Across Product Portfolio
3 Extensive R&D Capabilities Across Product Portfolio R&D Capabilities Innovative In-house Technologies 4 R&D Centers across formulations and API, 2 DSIR approved1 R&D scientists with 300+ doctorates 406 and post-graduates1 925 DCGI approvals1, along with + 923 FSSAI approvals Patent applications fi
Slide 24: Strategic Presence Across the Pharmaceutical Value Chain
4 Strategic Presence Across the Pharmaceutical Value Chain In addition to the CDMO Business, Akums is also engaged in manufacturing and sale of Branded Formulations, Trade Generics and APIs across domestic and overseas market Domestic Branded Formulations Exports Oriented Branded Formulations Dossie
Slide 25: Experienced Board of Directors
5 Experienced Board Directors of Board Sanjeev Jain Sandeep Jain Sanjay Sinha Sunil Kumar Thakur Managing Director Managing Director Whole Time Director Non-Executive Director • Co-founder and promoter • Co-founder and promoter • Over 4 decades of experience in • Partner at Quadria Capital and co- •
Slide 26: Slide 26
Akums Drugs and Pharmaceuticals — Q2 FY25 Earnings Presentation on 6ix